TickerGuard
Buy Day today: Neutral (47) Mixed market breadth · no major macro event
RCKT

Rocket Pharmaceuticals Inc

Healthcare · Biotechnology

2.50$ +2.2% vs. previous close Closing price · As of: Oct 7, 2026

Statements

Balance Sheet

Rocket Pharmaceuticals Inc (RCKT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 423 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet RCKT
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
140 130 118 111 105 102 217 208 195 251 242 309 300 372 373 353 335 591 576 535 530 497 460 432 417 552 515 462 599 566 499 446 394 528 471 421 368 330 285 423
139 128 117 110 104 101 185 135 129 209 200 264 246 308 280 255 233 487 472 430 425 392 354 326 311 364 338 312 447 378 345 293 242 378 324 277 228 193 150 290
83 30 25 28 49 79 171 53 38 111 124 65 89 185 191 163 82 297 253 265 246 233 131 188 197 141 65 45 226 56 35 39 66 164 50 33 76 78 50 225
138 126 115 109 103 100 183 132 127 206 197 258 241 304 276 250 229 483 466 427 421 389 347 321 307 356 331 307 437 373 330 279 236 372 318 271 223 189 144 284
– – – – – – – – – – – – – – – – – – – – – – 0.9 – – – – – – – 8.6 8.1 – – – – – – – –
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – -0.9 – – – – – – – – – – – – – – – – –
1.0 1.1 1.1 1.1 0.6 0.6 1.1 1.0 1.2 2.0 7.1 9.8 19 29 11 14 69 19 20 72 22 72 24 25 26 78 31 33 – – – – – – – – – – – –
0.0 0.0 0.0 0.0 0.0 0.0 31 31 31 31 31 31 31 31 31 31 31 31 31 31 31 31 31 31 31 39 39 39 39 39 39 39 39 39 39 39 39 39 39 39
0.0 0.0 0.0 0.0 0.0 0.0 31 31 31 – – – – 0.2 0.2 – – – – – – – – – – 26 26 26 25 25 25 25 25 25 25 25 25 25 25 25
55 56 55 54 54 54 47 50 51 57 65 60 68 65 87 87 94 87 96 46 45 42 43 44 50 62 56 59 58 74 58 62 64 64 59 67 54 53 47 54
5.9 7.2 5.3 4.0 3.8 4.1 7.3 10 10 15 21 15 22 18 21 21 32 33 40 25 24 22 23 24 30 39 31 34 33 49 33 38 40 41 35 43 31 30 24 31
– 4.8 2.5 2.9 2.8 – 39 40 0.0 0.0 0.9 0.9 0.9 1.0 2.3 2.4 7.1 7.1 7.3 7.6 2.5 2.6 2.5 2.4 2.4 2.5 2.6 3.0 2.9 2.7 2.9 2.9 2.8 2.9 2.9 2.9 2.9 2.9 2.9 3.0
1.8 1.6 1.9 0.4 0.4 0.5 0.1 0.1 0.0 0.0 18 -0.9 -0.9 -1.0 -2.3 -2.4 25 25 0.0 0.0 0.0 0.0 0.0 22 0.0 37 0.0 0.0 1.9 0.0 2.8 3.1 2.8 1.6 2.9 1.7 2.7 – 4.2 28
49 49 49 49 49 50 39 40 41 41 42 43 44 45 46 46 42 35 36 – – – – – – – – – – – – – – – – – – – – –
85 73 63 58 51 48 170 157 144 194 177 249 232 307 286 267 242 504 480 489 486 455 418 388 367 490 459 403 541 493 442 385 330 463 412 354 314 277 238 369
-226 -239 -250 -256 -264 -268 -47 -62 -79 -106 -125 -144 -163 -183 -208 -233 -262 -323 -363 -398 -448 -492 -535 -589 -647 -714 -772 -838 -900 -959 -1,021 -1,091 -1,158 -1,218 -1,279 -1,348 -1,399 -1,441 -1,489 -1,366
6.7 6.7 6.8 6.8 6.8 6.8 36 39 40 45 45 49 50 55 55 55 55 55 62 63 64 64 65 65 66 73 79 80 83 84 94 94 94 98 110 111 112 111 112 115

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?